Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program
Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ -- Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the...
Sihuan Pharmaceutical（0460.HK）: Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing
Accelerating the Layout of Diabetes and Complications HONG KONG, Jan. 4, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; stock code: 0460) is pleased to announce that the Group's Jilin Huisheng Biopharmaceutical Co., Ltd. ("Huisheng Biopharmaceutical"), a non-wholly owned subsidiary, has successfully completed...
China’s optimization of control measures lays solid foundation for COVID-19 response
BEIJING, Jan. 4, 2023 /PRNewswire/ -- A report from People's Daily: Local authorities and relevant departments in China have been making unremitting efforts recently to ensure the supply of medical resources, satisfy the demand for medicines and focus on the prevention and treatment of high-risk groups, building a solid defense line against COVID-19 that protects people's health. They have...
Pulnovo Medical Announces Dr. Mingdong Zhang, Former FDA Medical Device Officer Joins Scientific Advisory Board
SHANGHAI, Jan. 4, 2023 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM platform, announced the appointment of Dr. Mingdong Zhang to the company's Scientific Advisory Board (SAB). Dr. Zhang will provide guidance on Pulnovo Medical's clinical development and registration strategyand supporting the company's global development plan. Pulnovo Medical is a medical device company that focuses on innovative research...
Bioniq® Repair Toothpaste with 20% BioHAP*, scientifically proven to remineralise enamel and keeps teeth healthy and strong
HONG KONG, Jan. 4, 2023 /PRNewswire/ -- While most Westerners prefer trimmed meat and fish fillets, a vast majority of Asian diners enjoy eating their food off bones, picking flesh from carcasses, and gnawing on tendons, cartilage, and bones for gooey, chewy textures1. Hong Kong, a food paradise in Asia, is home to many popular Cantonese dishes like steamed...
Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST003, its first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1, has received IND clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA)....
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
MELBOURNE, Australia and SAN FRANCISCO, Jan. 3, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum (NIF). The...
Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test
IRVINE, Calif., Jan. 3, 2023 /PRNewswire/ -- Burning Rock (NASDAQ/LSE: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its OverC™ Multi-Cancer Detection Blood Test (MCDBT) has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA), which is the third of its...
Bridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023
SAN FRANCISCO and SEONGNAM, South Korea, Jan. 3, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis and inflammation, announced that the company is presenting at Biotech Showcase™ 2023. Pavel Printsev, Director of Business Development of Bridge Biotherapeutics, will provide an overview of the company as well as an...
Exclusive Pepaminto topper wins CES® 2023 Innovation Award
Mattress Topper developed exclusively for the Apple Watch®. MÜNSTER, Germany, Jan. 3, 2023 /PRNewswire/ -- Freezing, shivering, sweating - everyone's nighttime perception of warmth is different. The German Start-up Variowell Development asked 3.300 consumers in 5 countries globally. Over 50% answered that they or their partner often feel too hot often at...
